Home > Healthcare > Biotechnology > Bioservices > Oncology Based In-vivo CRO Market

Oncology Based In-vivo CRO Market Trends

  • Report ID: GMI12605
  • Published Date: Dec 2024
  • Report Format: PDF

Oncology Based In-vivo CRO Market Trends

The oncology-based in-vivo CRO market is evolving rapidly due to advancements in cancer research and the increasing demand for innovative drug development solutions, with several trends shaping the market.

 

  • The surge in immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, has led to increased demand for in-vivo studies to evaluate immune-oncology interactions. Syngeneic models, which support immunocompetent systems, are becoming essential in this segment.
     
  • Start-ups and mid-sized biotech companies are outsourcing preclinical research to CROs to leverage expertise and reduce costs. These companies focus on niche areas, fueling demand for specialized CRO services.
     
  • Additionally, artificial intelligence and machine learning are being integrated into in-vivo studies to improve data analysis, enhance model predictability, and reduce study timelines. Advanced imaging technologies (e.g., PET, MRI) are being combined with AI to provide real-time insights into tumor progression and treatment efficacy.
     
  • Moreover, pharmaceutical and biotech companies are forming strategic alliances with CROs to co-develop new therapies and expand access to advanced research models. For instance, in February 2021, Charles River Laboratories entered into a strategic partnership with Kibur Medical to provide exclusive access to Kibur's implantable microdevice. This collaboration aims to enhance in vivo preclinical oncology studies by enabling researchers to more accurately assess the efficacy of oncology compounds, both as individual treatments and in combination therapies.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oncology-based in-vivo CRO industry was valued at USD 1.4 billion in 2024 and is projected to grow at an 8.8% CAGR from 2025 to 2034, driven by the increasing demand for immuno-oncology therapies.

The preclinical testing segment held a 33.2% market share in 2024 due to its essential role in the drug development process, mandated by regulatory agencies like the U.S. FDA and EMA.

The U.S. led the North American oncology-based in-vivo CRO market in 2024, generating approximately USD 509 million, primarily due to significant investments in cancer research and a strong presence of pharmaceutical and biotechnology companies.

Key players in the market include Charles River Laboratories, Crown Bioscience, Eurofins Scientific, Evotec SE, ICON plc, IMV, Laboratory Corporation of America Holdings, Medidata, Merck KGaA, OncoOne, Pharmaron, and Taconic Biosciences.

Oncology Based In-vivo CRO Market Scope

Buy Now


Premium Report Details

  • Base Year: 2024
  • Companies covered: 15
  • Tables & Figures: 123
  • Countries covered: 18
  • Pages: 140
 Download Free Sample